Business Overview

Jan 2011
Date Founded
Active
Operating Status
Revenue Generating
Revenue Stage
B2B
Business Model
120
Employees

The faster we diagnose, the faster we can treat. At Sight Diagnostics, we aim to improve health through fast, accurate and convenient diagnostic testing.Sights latest analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes, not hours. Its compact: designed to be used by anyone, anywhere.Sights method, developed over a decade of research, represents a step-change in diagnostic technology. Our analyzers create a digital version of your blood, by capturing 1,000 highly detailed images of a finger prick sample, which is then interpreted by our proprietary algorithms. Sights first product was focused on detecting Malaria, used in 24 countries, and has delivered almost 1 million tests to date.At Sight, exceptional individuals work together to achieve extraordinary things. We have rapidly growing offices in London, New York, and Tel Aviv.

Business Stage
Launched

Founders

Sight Diagnostics
Yossi Pollak
CEO
Sight Diagnostics
Daniel Levner

Board Members and Advisors

Sight Diagnostics
Adi Shay
Board Member
Sight Diagnostics
Falk Fish
Board Advisor

Funding Rounds

$124 M

Total Funding
11
No. of Investors

5

Funding Rounds
2.20x
Funding Growth

New wpDataTable

Date Announced

Funding Round

Amount Raised

Investors

AI Technology Stack

15
AI Team Size

Similar Startups

STATUS
Inactive
STATUS
Active
FUNDING
$4.5 M
FUNDING STAGE
Series A
AI Team Ratio
STATUS
Active
STATUS
Active
AI Team Ratio
STATUS
Active
STATUS
Active
STATUS
Active
FUNDING STAGE
Seed
AI Team Ratio
STATUS
Active
AI Team Ratio
STATUS
Active
FUNDING
$1.1 M
FUNDING STAGE
Grant
STATUS
Active
FUNDING
$9 M
FUNDING STAGE
Seed
STATUS
Active
FUNDING
$3.5 M
FUNDING STAGE
Seed
AI Team Ratio
STATUS
Active
FUNDING
$156.7 M
FUNDING STAGE
Series D+
AI Team Ratio
STATUS
Active
FUNDING
$7.6 M
FUNDING STAGE
Series A
STATUS
Active

Startup Snapshot

Operating Status
Active
AI Team Size
15
Total Funding
$124 Million
Founded
January 2011
Funding Stage
Series D
Valuation (Post-Money)
As of July 2020
$500 Million

Competitors

Our mission is to translate the complex signals of the immune system into simple diagnostic in...

FEATURED VIDEO

Sign up for free

  • Save profiles to your list
  • View all funding rounds
  • Advanced sorting filter access
  • Search investment rounds
  • Search exit events

Fundraising Contact

Submission Received

Thanks for your contribution.

Your edits are under review and will be visible soon.